Baidu
map

论文与基金

订阅

MedSci主页 / 所有栏目 / 论文与基金

江苏省中医药局基金申请样本(2006年)

2009-12-22 MedSci原创 MedSci原创

基金
关注

五倍子瘢痕膏治疗瘢痕疙瘩疗效、副作用及复发情况的比较研究.rar

五倍子瘢痕膏治疗瘢痕疙瘩疗效、副作用及复发情况的比较研究.rar

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2667, encodeId=8ac6266e3e, content=谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=483429131, createdName=qwu9516, createdTime=Mon Aug 08 19:40:00 CST 2011, time=2011-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077152, encodeId=586020e715253, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Apr 11 09:06:00 CST 2010, time=2010-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923963, encodeId=0150192396322, content=<a href='/topic/show?id=3cc864345d6' target=_blank style='color:#2F92EE;'>#江苏省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64345, encryptionId=3cc864345d6, topicName=江苏省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jun 24 07:06:00 CST 2010, time=2010-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669309, encodeId=57d916693098d, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Tue Jun 15 08:06:00 CST 2010, time=2010-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408578, encodeId=a52d14085e8e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Dec 24 01:06:00 CST 2009, time=2009-12-24, status=1, ipAttribution=)]
    2011-08-08 qwu9516

    谢谢!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2667, encodeId=8ac6266e3e, content=谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=483429131, createdName=qwu9516, createdTime=Mon Aug 08 19:40:00 CST 2011, time=2011-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077152, encodeId=586020e715253, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Apr 11 09:06:00 CST 2010, time=2010-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923963, encodeId=0150192396322, content=<a href='/topic/show?id=3cc864345d6' target=_blank style='color:#2F92EE;'>#江苏省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64345, encryptionId=3cc864345d6, topicName=江苏省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jun 24 07:06:00 CST 2010, time=2010-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669309, encodeId=57d916693098d, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Tue Jun 15 08:06:00 CST 2010, time=2010-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408578, encodeId=a52d14085e8e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Dec 24 01:06:00 CST 2009, time=2009-12-24, status=1, ipAttribution=)]
    2010-04-11 124987c6m36暂无昵称

    #中医药局#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2667, encodeId=8ac6266e3e, content=谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=483429131, createdName=qwu9516, createdTime=Mon Aug 08 19:40:00 CST 2011, time=2011-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077152, encodeId=586020e715253, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Apr 11 09:06:00 CST 2010, time=2010-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923963, encodeId=0150192396322, content=<a href='/topic/show?id=3cc864345d6' target=_blank style='color:#2F92EE;'>#江苏省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64345, encryptionId=3cc864345d6, topicName=江苏省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jun 24 07:06:00 CST 2010, time=2010-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669309, encodeId=57d916693098d, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Tue Jun 15 08:06:00 CST 2010, time=2010-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408578, encodeId=a52d14085e8e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Dec 24 01:06:00 CST 2009, time=2009-12-24, status=1, ipAttribution=)]
    2010-06-24 智者为医08

    #江苏省#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2667, encodeId=8ac6266e3e, content=谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=483429131, createdName=qwu9516, createdTime=Mon Aug 08 19:40:00 CST 2011, time=2011-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077152, encodeId=586020e715253, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Apr 11 09:06:00 CST 2010, time=2010-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923963, encodeId=0150192396322, content=<a href='/topic/show?id=3cc864345d6' target=_blank style='color:#2F92EE;'>#江苏省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64345, encryptionId=3cc864345d6, topicName=江苏省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jun 24 07:06:00 CST 2010, time=2010-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669309, encodeId=57d916693098d, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Tue Jun 15 08:06:00 CST 2010, time=2010-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408578, encodeId=a52d14085e8e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Dec 24 01:06:00 CST 2009, time=2009-12-24, status=1, ipAttribution=)]
    2010-06-15 zhzhxiang

    #样本#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2667, encodeId=8ac6266e3e, content=谢谢!, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=483429131, createdName=qwu9516, createdTime=Mon Aug 08 19:40:00 CST 2011, time=2011-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077152, encodeId=586020e715253, content=<a href='/topic/show?id=af892152021' target=_blank style='color:#2F92EE;'>#中医药局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21520, encryptionId=af892152021, topicName=中医药局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85152500072, createdName=124987c6m36暂无昵称, createdTime=Sun Apr 11 09:06:00 CST 2010, time=2010-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923963, encodeId=0150192396322, content=<a href='/topic/show?id=3cc864345d6' target=_blank style='color:#2F92EE;'>#江苏省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64345, encryptionId=3cc864345d6, topicName=江苏省)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu Jun 24 07:06:00 CST 2010, time=2010-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669309, encodeId=57d916693098d, content=<a href='/topic/show?id=9d7b620395d' target=_blank style='color:#2F92EE;'>#样本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62039, encryptionId=9d7b620395d, topicName=样本)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f33226554040, createdName=zhzhxiang, createdTime=Tue Jun 15 08:06:00 CST 2010, time=2010-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408578, encodeId=a52d14085e8e5, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Dec 24 01:06:00 CST 2009, time=2009-12-24, status=1, ipAttribution=)]
    2009-12-24 cathymary

    #医药#

    0

相关资讯

2009中国科技论文统计结果显示:中国国际影响力提升

2009年11月27日，中国科学技术信息研究所在北京国际会议中心召开了“2009中国科技论文统计结果发布会”。发布了2008年我国国际国内论文数量和影响情况，首次公布了表现不俗的中国论文状况分析，发布了2008年中国百种杰出学术期刊名单，以及2008年中国百篇最具影响国际和国内论文。科技部、中宣部、教育部、卫生部、解放军总后卫生部、新闻出版总署、中

给Nature投稿：一个失败的故事

信源：司华博客60多年前（45，46年），浙江大学教师贝时璋，王淦昌，束星北，何增禄四位教授在Nature上共发表了6篇论文。自那以后浙江大学教师在就没有在nature上以第一作者（或通信作者），且第一单位发表过论文（第二单位还是有的，例如童利民教授）。值得一提的是，上个月18日刘树生教授的一篇论文，实现了第二个顶级期刊Science零的突破。近20年来，浙大每年都有一些教授向Nature，Sci

英文SCI论文写作、投稿过程中的注意事项

【写作前准备】 1、自己的实验结果是否够发一篇SCI文章？ 2、适合发表在什么杂志？是选择专业期刊？还是综合期刊？ 3、为什么类型的投稿（Types of submission）？比如Articles（论著）；Reviews（综述）；Reports（报告）；Letter to editor（来信）等。 4、该杂志的影响因子（Impact factor）是多少，每年发表多少文章？是否有过本土中国人在

MedSci参加第6届中国蛋白质组学大会

2009年7月29日至31日在江苏泰州举办的第6届中国蛋白质组学大会，本次大会由中国生物化学与分子生物学会蛋白质组学专业委员会(CNHUPO)主办，北京蛋白质组研究中心和复旦大学共同承办。MedSci工作人员参加了此次盛会。 大会开幕式由中国生物化学与分子生物学会蛋白质组学专业委员会执行主席杨晓明主持，中国生物化学与分子生物学会蛋白质组学专业委

论文撰写的主要内容与写作技巧

(一)题目　　医学论文担负着传播医学信息、进行学术交流、指导临床实践的重任，论文的题目是信息的集中点，更要求论文命题能准确反映文章内容，提供有价值的信息，因此，论文题目要求具体、简洁、鲜明、确切而有特异性和可检索性。　　1、论文题目要有具体性。题目不具体是初学者撰写医学论文时常见的缺点，例如“矽肺的预防”，“乙型肝炎的流行病学调查”等等。　　2、论文题目要有简洁性。题目应简短、精练，

英文论文写作、投稿过程中的注意事项

英文论文写作、投稿过程中的注意事项 tangdl2000的个人经验【写作前准备】 1、自己的实验结果是否够发一篇SCI文章？2、适合发表在什么杂志？是选择专业期刊？还是综合期刊？3、为什么类型的投稿（Types of submission）？比如Articles（论著）；Reviews（综述）；Reports（报告）；Letter to editor（来信）等。4、该杂志的影响因子（Impac

Baidu
map
Baidu
map
Baidu
map